Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which...
This is an interesting stock and I think this will go up quickly strictly due to supply and demand
Fundamental & Chart Not for investment advice, personal notes only Chart: identified key area of support, concerning current H&S pattern, potential downside to next support indicate 17% drop. CMF shows weakness, spending a lot of times in the negatives. So far trend line remains intact, neckline of H&S shows no particular bearish...
$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...